The Cuban biotechnology’s impact on cancer control and innovative therapeutic product developed by the Molecular Immunology Center (CIM), will be presented at the XXXI International Fair of Havana (FIHAV-2013), which began this Sunday in this capital.
In a round of negotiations, scheduled for November 7 in the fairgrounds of EXPOCUBA, Cuba will present a multimedia made for VAXIRA, last therapeutic vaccine for the treatment of lung cancer, with promising results, CIM scientists announced.
The institution conducts more than 60 clinical trials in Cuba for several diseases, most notably cancer, which is the leading cause of death in the country since 2012.
In an exclusive interview with ACN, Dr. Mayra Ramos, head of the department of Clinical Trials CIM - within the BioCubaFarma business group, announced that they are developing new therapeutic vaccines and monoclonal antibodies.
In the latter type the Caribbean nation has registered nimotuzumab for patients with tumors of the head and neck, brain, both in adults and in children.
She also said that this product has been applied in colorectal oncogenic diseases, hepatocellular, lung cancer, brain metastases of malignant tumor in those and other locations.
CIM studies, in conjunction with the Coordinating Center for Clinical Trials, also have demonstrated efficacy with therapeutic vaccines recorded in Cuba for the treatment of lung cancer: the CIMAVAX-EGF and Racotumomab (Vaxira).
We have also performed other clinical trials with these immunogens in prostate, breast and colon cancers, the specialist said.
From the beginning of this year they are carrying out a new clinical trial of VAXIRA, in the neighborhood clinics, with great results, Ramos added.